Iceland launches massive screening study for early cancer detection
NCT ID NCT03327597
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is screening over 80,000 people in Iceland to see if early detection of a condition called MGUS can prevent or improve outcomes for multiple myeloma, a type of blood cancer. Participants are randomly assigned to routine care or closer monitoring. The goal is to compare survival and complications between the groups.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could show that population-wide screening for MGUS helps catch multiple myeloma earlier, potentially improving survival and reducing treatment complications.
- What could go wrong
- This is an observational screening study, not a treatment trial. It may not prove that screening saves lives, and there is a risk of overdiagnosis or unnecessary anxiety.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Iceland
Reykjavik, Iceland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gene clues may unlock new treatments for bone marrow cancer
- New blood test screening targets hidden cancer in black communities
- Gut bacteria drug shows promise against blood disorder
- Turmeric and black pepper extract shows promise in slowing early cancers
- 1,000 volunteers help scientists unlock the mystery of myeloma progression
- New italian network aims to catch rare blood disease earlier